We know CP673451 datasheet that clinical experience about one patient can change the world of medical science,

and therefore it is still important to publish case reports. For that reason, we have now decided to launch a new journal, the International Cancer Conference Peptide 17 journal (ICCJ), to accept excellent case reports, thereby contributing to clinical education and discussion. This is a unique, online journal, providing benefits such as quick review and publication, along with free color presentation of figures and videos. Additionally, in the future, readers will be able to participate in the discussions through letters and commentary in the journal’s cancer board conferences. On behalf of the Japan Society of Clinical Oncology, we sincerely look forward to your submission of cancer case reports and other contributions to the International Cancer Conference Journal (ICCJ). Journal title: International Cancer Conference Journal Editor-in-chief: Yoshiharu Sakai, MD Published format: Electronic online edition only Frequency of publication: 4 times per year (issued quarterly) Contents: Clinical Reviews or Cancer Board

Conferences, 1 or 2 per issue; Case Reports, approximately 10 per issue Initial publication: January 2012 Submission and publication cost: Free of charge, including color pages Submission guidance: Use this website the online system Editorial Manager starting in May 2011 [Inquiries] c/o Invention Center of the Kinki Districts (Kinki Chiho Hatsumei ID-8 Center), 14 Yoshidakawaramachi, Sakyo-ku, Kyoto 606-8305, Japan Fax +81-75-761-9724 E-mail: [email protected] International Journal of Clinical Oncology Editor-in-Chief Ikuo Konishi, MD”
“Background Antimicrobial resistance is an increasing challenge

of global proportions [1]. Special emphasis has been put on Gram negative bacteria producing enzymes conferring resistance against beta lactam antibiotics, such as third and fourth generation cephalosporins, monobactams and carbapenems, commonly known as extended spectrum beta-lactamases (ESBLs) [2-4]. ESBLs are associated with higher morbidity and mortality, rising health care costs [5], potential for foodborne transmission [6,7] and asymptomatic carriage [8]. ESBL-producing bacteria most often reside in the intestine of humans and animals, and may thus be difficult to control and eradicate [9,10]. Plasmid mediated ESBL genes can be transferred between different strains of bacteria and between different bacterial species and genera within the Enterobacteriaceae family [11]. Co-resistance to other groups of antibiotics is frequently observed in ESBL-producing organisms, which makes the choice of effective treatment even more limited [12]. In the Nordic countries, recent studies state that the main risk factor for acquiring ESBL-producing bacteria is travel abroad [13-15]. Asymptomatic infections with Salmonella and Shigella do occur [16,17]. When screening for fecal carriage of ESBL, the methods must ensure reliable detection also of these bacterial species.